ResMed (RMD) has been an active player in the investment sector. RMD has shown strength in its Q1 results, leading to increased interest from various investor entities such as Baird and Mizuho, who maintain outperformance ratings for the company. Meanwhile, Genus Capital Management Inc., Sienna Gestion and Horizon Investment Services LLC are among those who have increased their shares in the company. Pre-earning report speculations suggest further growth for the company. Its resilience amidst challenges such as a patent lawsuit attests to its long-term growth potential. Disposals of RMD shares were also reported from different entities, including Bank of New York Mellon Corp and Bank of Montreal Can, indicating a fluid market movement regarding RMD. Price targets are being adjusted by various firms including Baird and Keybanc, generally leaning towards a positive adjustment. RMD's steady dividend boosts its attractiveness to investors and its Q3 earnings beat estimates, strengthening its growth stock narrative. Institutional owners own approximately 74% of the company. Finally, RMD's strategic innovations such as the launch of a new mask platform and investment in U.S. Operations are indicative of its forward-thinking approach.
Resmed RMD News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 08 Nov 2025 20:53:45 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor -6
